Shots: The discontinuation is based on pre-planned interim analyses of P-III studies assessing Pimodivir + SOC vs SOC as monothx. in hospitalized & non-hospitalized patients with influenza A The therapy […]readmore
Tags : Development
Shots: AstraZeneca has expanded the development of AZD1222 into P-III D8110C00001 study to assess its safety, efficacy, and immunogenicity. BARDA has funded the P-III study to accelerate the development of […]readmore
Shots: Sarepta to fund four research programs at the UF and will get an exclusive option to develop any new therapeutic compounds resulting from the funded research programs. The projects […]readmore
Since the virus outbreak in China, all eyes are on the most awaited Covid-19 vaccine offering a glimmer of hope. Abide by social distancing, wearing a mask, and frequent hand […]readmore
Shots: Ovid will collaborate with UConn’s Stormy J. Chamberlain and secures exclusive access to identified genetic sequences for shRNA-based therapy. Ovid plans to leverage its translational medicine capabilities and drug […]readmore
Shots: Esperion to receive $60M up front, $450M as development & commercial milestone and is eligible to receive 15-30% royalties in the sale of products in Japan. Otsuka will get […]readmore
Biotech
Samsung Biologics Signs Multi-Product Development and Manufacturing Agreement with ImmuneOncia
Shots: The two companies expand their 2018 agreement to develop and manufacture five candidates from ImmuneOncia’s pipeline. The partners expand the collaboration to bring new treatments such as IMC-002 for […]readmore
Shots: Sanofi and MD Anderson collaborated for 5yrs. to ramp up the development of investigational treatments, including targeted and immune-therapies for oncology patients. The alliance will support investigations into additional […]readmore
Shots: Samsung Biologics to offer CDO services from cell line development, process development, non-clinical & clinical material manufacturing, to IND submission for global clinical trials of STM418 The companies have […]readmore
Shots: Yumanity will receive $500M upfront and milestones along with royalties on net sales of therapies, in exchange Merck to get an exclusive right to two novels Yumanity’s pipeline programs […]readmore